Adipocyte protein 2: Difference between revisions
Jump to navigation
Jump to search
m (Bot: HTTP→HTTPS) |
m (Open access bot: add pmc identifier to citation with #oabot.) |
||
| Line 1: | Line 1: | ||
{{lowercase|aP2}} | {{lowercase|aP2}} | ||
{{Infobox_gene}} | {{Infobox_gene}} | ||
'''aP2''' ([[adipocyte]] Protein 2)<ref name="pmid2481498">{{cite journal | vauthors = Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, Bernlohr DA | title = Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA | journal = Biochemistry | volume = 28 | issue = 22 | pages = 8683–90 | year = 1989 | pmid = 2481498 | doi = 10.1021/bi00448a003 }}</ref> is a [[carrier protein]] for [[fatty acids]] that is primarily expressed in adipocytes and [[macrophage]]s. aP2 is also called''' fatty acid binding protein 4''' ('''FABP4'''). Blocking this protein either through genetic engineering or drugs<ref>[https://www.forbes.com/forbeslife/health/feeds/hscout/2006/07/14/hscout533816.html Forbes health article July 14, 2006]</ref><ref>[http://www.medicinenet.com/script/main/art.asp?articlekey=62919 Medicinenet.com]</ref> has the possibility of treating heart disease,<ref name="pmid11385507">{{cite journal | vauthors = Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF | title = Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis | journal = Nat. Med. | volume = 7 | issue = 6 | pages = 699–705 | year = 2001 | pmid = 11385507 | doi = 10.1038/89076 }}</ref> diabetes,<ref name="pmid17554340">{{cite journal | vauthors = Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS | title = Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 | journal = Nature | volume = 447 | issue = 7147 | pages = 959–65 | year = 2007 | pmid = 17554340 | doi = 10.1038/nature05844 }}</ref> asthma,<ref name="pmid16841093">{{cite journal | vauthors = Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS, Rolph MS | title = The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation | journal = J. Clin. Invest. | volume = 116 | issue = 8 | pages = 2183–2192 | year = 2006 | pmid = 16841093 | doi = 10.1172/JCI24767 | pmc = 1501108 }}</ref> obesity,<ref name="pmid16054052">{{cite journal | vauthors = Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS | title = Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes | journal = Cell Metab. | volume = 1 | issue = 2 | pages = 107–19 | year = 2005 | pmid = 16054052 | doi = 10.1016/j.cmet.2004.12.008 }}</ref> and fatty liver disease.<ref name="pmid16148539">{{cite journal | vauthors = Makowski L, Hotamisligil GS | title = The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis | journal = Curr. Opin. Lipidol. | volume = 16 | issue = 5 | pages = 543–8 | year = 2005 | pmid = 16148539 | doi = 10.1097/01.mol.0000180166.08196.07 }}</ref> | '''aP2''' ([[adipocyte]] Protein 2)<ref name="pmid2481498">{{cite journal | vauthors = Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, Bernlohr DA | title = Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA | journal = Biochemistry | volume = 28 | issue = 22 | pages = 8683–90 | year = 1989 | pmid = 2481498 | doi = 10.1021/bi00448a003 }}</ref> is a [[carrier protein]] for [[fatty acids]] that is primarily expressed in adipocytes and [[macrophage]]s. aP2 is also called''' fatty acid binding protein 4''' ('''FABP4'''). Blocking this protein either through genetic engineering or drugs<ref>[https://www.forbes.com/forbeslife/health/feeds/hscout/2006/07/14/hscout533816.html Forbes health article July 14, 2006]</ref><ref>[http://www.medicinenet.com/script/main/art.asp?articlekey=62919 Medicinenet.com]</ref> has the possibility of treating heart disease,<ref name="pmid11385507">{{cite journal | vauthors = Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF | title = Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis | journal = Nat. Med. | volume = 7 | issue = 6 | pages = 699–705 | year = 2001 | pmid = 11385507 | doi = 10.1038/89076 | pmc = 4027052 }}</ref> diabetes,<ref name="pmid17554340">{{cite journal | vauthors = Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS | title = Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 | journal = Nature | volume = 447 | issue = 7147 | pages = 959–65 | year = 2007 | pmid = 17554340 | doi = 10.1038/nature05844 | pmc = 4076119 }}</ref> asthma,<ref name="pmid16841093">{{cite journal | vauthors = Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS, Rolph MS | title = The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation | journal = J. Clin. Invest. | volume = 116 | issue = 8 | pages = 2183–2192 | year = 2006 | pmid = 16841093 | doi = 10.1172/JCI24767 | pmc = 1501108 }}</ref> obesity,<ref name="pmid16054052">{{cite journal | vauthors = Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS | title = Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes | journal = Cell Metab. | volume = 1 | issue = 2 | pages = 107–19 | year = 2005 | pmid = 16054052 | doi = 10.1016/j.cmet.2004.12.008 }}</ref> and fatty liver disease.<ref name="pmid16148539">{{cite journal | vauthors = Makowski L, Hotamisligil GS | title = The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis | journal = Curr. Opin. Lipidol. | volume = 16 | issue = 5 | pages = 543–8 | year = 2005 | pmid = 16148539 | doi = 10.1097/01.mol.0000180166.08196.07 | pmc = 3904771 }}</ref> | ||
== See also == | == See also == | ||
Revision as of 21:42, 2 June 2018
| VALUE_ERROR (nil) | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Aliases | |||||||
| External IDs | GeneCards: [1] | ||||||
| Orthologs | |||||||
| Species | Human | Mouse | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
|
| |||||
| RefSeq (mRNA) |
|
| |||||
| RefSeq (protein) |
|
| |||||
| Location (UCSC) | n/a | n/a | |||||
| PubMed search | n/a | n/a | |||||
| Wikidata | |||||||
| |||||||
aP2 (adipocyte Protein 2)[1] is a carrier protein for fatty acids that is primarily expressed in adipocytes and macrophages. aP2 is also called fatty acid binding protein 4 (FABP4). Blocking this protein either through genetic engineering or drugs[2][3] has the possibility of treating heart disease,[4] diabetes,[5] asthma,[6] obesity,[7] and fatty liver disease.[8]
See also
References
- ↑ Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, Bernlohr DA (1989). "Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA". Biochemistry. 28 (22): 8683–90. doi:10.1021/bi00448a003. PMID 2481498.
- ↑ Forbes health article July 14, 2006
- ↑ Medicinenet.com
- ↑ Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF (2001). "Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis". Nat. Med. 7 (6): 699–705. doi:10.1038/89076. PMC 4027052. PMID 11385507.
- ↑ Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS (2007). "Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2". Nature. 447 (7147): 959–65. doi:10.1038/nature05844. PMC 4076119. PMID 17554340.
- ↑ Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS, Rolph MS (2006). "The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation". J. Clin. Invest. 116 (8): 2183–2192. doi:10.1172/JCI24767. PMC 1501108. PMID 16841093.
- ↑ Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS (2005). "Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes". Cell Metab. 1 (2): 107–19. doi:10.1016/j.cmet.2004.12.008. PMID 16054052.
- ↑ Makowski L, Hotamisligil GS (2005). "The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis". Curr. Opin. Lipidol. 16 (5): 543–8. doi:10.1097/01.mol.0000180166.08196.07. PMC 3904771. PMID 16148539.
External links
- FABP4+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
- Human FABP4 genome location and FABP4 gene details page in the UCSC Genome Browser.
 | This article on a gene on human chromosome 8 is a stub. You can help Wikipedia by expanding it. |